A 24 Week, Open-Label Study to Evaluate the Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Prurigo Nodularis

Inclusion Criteria: 1. Male or female adult 18-64 years of age at time of screening. 2. Diagnosis of prurigo nodularis for ≥ 3 months. 3. Moderate-to-Severe prurigo nodularis as determined by at least 10 PN lesions on legs and/or arms and/or trunk at screening and baseline . 4. Failure of at least a 2-week course of medium to super potent TCS or TCS is not medically advisable for subject. 5. Females of childbearing potential must not have a positive serum pregnancy test at the Screening Visit and must have a negative urine pregnancy test at the Baseline Visit prior to study drug dosing. Note:…